Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From eGenesis Inc.
Start-Up Quarterly Statistics: Financings Surged In Q4 While M&A Waned
A review of biopharma start-up dealmaking and financing activity from October through December 2019, based on data from Strategic Transactions, showed a large rise in fundraising transactions from Q3 to Q4 of last year.
Venture Funding Deals: Sumitomo Alliance With Roivant Takes Shape
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced October to November.
Finance Watch: Pfizer Ventures' Dalton Makes Sense Of Neuroscience Focus Within New $600m VC Fund Commitment
Venture Capital Edition: Pfizer deprioritized neuroscience as an early R&D focus earlier this year, but will stay involved by spending 25% of the $600m added to its venture fund on neurology investments. Also, China VC investment keeps up fast pace and Alta Partners closes a new $130m health care fund.
Global CRISPR Revolution Gathers Pace, Raising Hopes – And Concerns
CRISPR technology was invented just five years ago but is so accurate, versatile, easy to use, and inexpensive that it has spread quickly through biology laboratories, giving researchers new tools to interrogate biology and make precise alterations to an organism’s genetic material, offering its potential use in a wide array of therapies.
- Gene Therapy, Cell Therapy
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.